A Microarray, Validation, and Gene-Enrichment Approach for Assessing Differentially Expressed Circulating miRNAs in Obese and Lean Heart Failure Patients: A Case–Control Study
Authors:
- Douglas dos Santos SoaresDSDouglas dos Santos Soares
- Amanda LopesALAmanda Lopes
- Mariana Recamonde-MendozaMRMariana Recamonde-Mendoza
- Rodrigo Haas BuenoRBRodrigo Haas Bueno
- Raquel CalloniRCRaquel Calloni
- Nadine ClausellNCNadine Clausell
- Santiago Alonso Tobar LeitãoSantiago Alonso Tobar Leitão
- Andreia BioloABAndreia Biolo
Open Access
- 27 September 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9475
Abstract
Obesity is a risk factor associated with cardiovascular diseases that may lead to heart failure (HF). However, in HF, overweight and obese patients have longer survival than underweight patients, a phenomenon known as the obesity paradox. MiRNAs play a fundamental role in gene regulation involved in obesity and HF. The main objective of this study was to identify and validate differentially expressed circulating miRNAs in HF–obese and HF–lean patients. This case–control study was carried out in two phases: discovery and validation. In the discovery phase, plasma samples from 20 HF patients and from 10 healthy controls were analyzed using the miRNA 4.0 Affymetrix GeneChip array. Differentially expressed miRNAs were ranked and selected for validation. In this phase, plasma miRNAs -451a, -22-3p, and -548ac from 80 patients and controls were analyzed by qPCR. Target analysis and functional enrichment analysis were performed. When comparing HF–lean and HF–obese groups compared to controls, miRNAs -451a and -22-3p were up-regulated in both discovery and validation phases, while -548ac was down-regulated in the discovery phase and up-regulated in the validation phase, indicating that miRNA changes are independent of obesity. These miRNAs regulate genes and different biological processes associated with metabolic, morphological, and functional outcomes.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (16/2551-0000520-6)
- the Hospital de Clínicas de Porto Alegre (2019-470)
This publication has 35 references indexed in Scilit:
- Heart Failure and Obesity: Translational Approaches and Therapeutic Perspectives. A Scientific Statement of the Heart Failure Association of the ESCEuropean Journal of Heart Failure, 2025
- Update on obesity, the obesity paradox, and obesity management in heart failureProgress in Cardiovascular Diseases, 2024
- Circulating Levels of MicroRNAs in Hypertrophic Cardiomyopathy: The Relationship With Left Ventricular Hypertrophy, Left Atrial Dilatation and Ventricular Depolarisation-Repolarisation ParametersHeart, Lung and Circulation, 2022
- MicroRNA-451a attenuates angiotensin II–induced cardiac fibrosis and inflammation by directly targeting T-box1Journal of Physiology and Biochemistry, 2021
- The Interaction of Cardiorespiratory Fitness With Obesity and the Obesity Paradox in Cardiovascular DiseaseProgress in Cardiovascular Diseases, 2017
- Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT studyInternational Journal of Cardiology, 2017
- Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial PopulationsJACC: Heart Failure, 2016
- Circulating microRNAs in obese and lean heart failure patients: A case–control study with computational target prediction analysisGene, 2015
- Impact of Obesity and the Obesity Paradox on Prevalence and Prognosis in Heart FailureJACC: Heart Failure, 2013
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studiesThe Lancet, 2009